What is the half-life of tesamorelin?
Tesamorelin has a plasma half-life of approximately 25-40 minutes in humans following subcutaneous administration. The short half-life supports once-daily dosing — the trans-3-hexenoyl N-terminal modification protects against DPP-IV cleavage and extends effective in-vivo activity beyond what native GHRH (1-44) would deliver, but not into the multi-day range that engineered long-acting peptides achieve.
What the research literature says
Tesamorelin is a synthetic analogue of human growth hormone-releasing hormone (GHRH 1-44) with an N-terminal trans-3-hexenoyl modification that confers resistance to dipeptidyl peptidase IV cleavage. The modification extends the in-vivo half-life sufficiently to support once-daily subcutaneous dosing while preserving the agonist activity at the pituitary GHRH receptor on somatotroph cells.
The compound’s clinical pharmacokinetic profile was characterised across the development program for HIV-associated lipodystrophy that led to FDA approval. The Tomlinson drug evaluation consolidates the early development and pharmacology framework (PMID 17086939). The Falutz NEJM trial established the once-daily 2 mg subcutaneous dosing regimen that supports reduction in visceral adipose tissue in HIV-infected patients (PMID 18057338).
The downstream pharmacology — GH release from the pituitary and subsequent IGF-1 elevation — operates on a longer time scale than the parent tesamorelin’s plasma half-life. The pulsatile GH release following each dose drives hepatic IGF-1 synthesis over 12-24 hours, with steady-state IGF-1 elevation established within the first week of once-daily dosing (PMID 20554713 — pooled phase 3 analysis).
Why this matters in research context
The short half-life of tesamorelin itself contrasts with the multi-day IGF-1 response it drives. Researchers studying GHRH-axis pharmacology with tesamorelin should distinguish between the direct GHRH-receptor engagement (short-duration, governed by tesamorelin half-life) and the downstream GH/IGF-1 axis response (longer-duration, governed by downstream tissue pharmacokinetics). The published clinical trials measure visceral adiposity reduction over 26-52 weeks of daily dosing, which is the integrated tissue-level response over many GH pulses.
Related compounds
- Tesamorelin 10mg — the compound covered by this answer
- CJC-1295 No DAC 10mg — alternative GHRH analogue with shorter half-life (~30 min) and even more pulsatile profile
Related research questions
- What is the half-life of CJC-1295 No DAC?
- What is the half-life of ipamorelin?
- Can CJC-1295 be stacked with ipamorelin?
References
- Tomlinson B. Drug evaluation: tesamorelin, a synthetic human growth hormone releasing factor. Curr Opin Investig Drugs 2006;7(10):952-961. [PMID 17086939]
- Falutz J et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med 2007;357(23):2359-2370. [PMID 18057338]
- Falutz J et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab 2010;95(9):4291-4304. [PMID 20554713]
Research-questions pages describe research-context use of peptide-research terminology. They do not constitute medical, veterinary, or clinical advice. Tesamorelin is sold strictly as a research-grade reagent for laboratory and bench research applications.